OCREVUS Access Solutions
Committed to providing assistance during your patients’ treatment,
including access, reimbursement and infusion coordination
support.
PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.
SMN=Statement of Medical Necessity.
Important Safety Information & Indication
Indications
OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.
Contraindications
OCREVUS is contraindicated in patients with active hepatitis B virus infection and in patients with a history of life-threatening infusion reaction to OCREVUS.
Warnings and Precautions
Infusion Reactions:
Management recommendations for infusion reactions depend on the type and severity of the reaction. Permanently discontinue OCREVUS if a life-threatening or disabling infusion reaction occurs.
Infections:
Delay OCREVUS administration in patients with an active infection until the infection is resolved. Vaccination with live-attenuated or live vaccines is not recommended during treatment with OCREVUS and after discontinuation, until B-cell repletion.
Malignancies:
An increased risk of malignancy, including breast cancer, may exist with OCREVUS.
Most Common Adverse Reactions
RMS: The most common adverse reactions in RMS trials (incidence ≥10% and >REBIF): upper respiratory tract infections and infusion reactions.
PPMS: The most common adverse reactions (≥10% and >placebo): upper respiratory tract infections, infusion reactions, skin infections, and lower respiratory tract infections.
For additional safety information, please see the full Prescribing Information and Medication Guide.